A digital therapy that could reduce the severity of the symptoms of chronic tic disorders and Tourette syndrome has been conditionally recommended for NHS use. These cookies remember information that ...

Your organisation needs to be registered as a stakeholder before we can accept comments. Not eligible? Contact the stakeholder organisation that most closely represents your interests and pass your ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee D. Committee members are asked to declare any interests in the technology being ...

Osimertinib (Tagrisso, AstraZeneca) with pemetrexed and platinum-based chemotherapy is indicated for 'the first-line treatment of adult patients with advanced NSCLC whose tumours have EGFR exon 19 ...

Osimertinib with pemetrexed and platinum-based chemotherapy (Tagrisso) is available on the NHS as a possible treatment for advanced non-small-cell lung cancer that has not been treated before. It is ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

The following considerations around implementing the evidence generation process have been identified through working with system partners: ...

There is a simple discount patient access scheme for brentuximab vedotin. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...